Aug. 7, 2018—Beckman Coulter announced commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing that uses direct minimum inhibitory concentrations for detection of antimicrobial resistance.
The system’s delivery of gold-standard MIC accuracy helps laboratories achieve their operational goals by reducing costs associated with confirmatory testing, the company says. Added workflow enhancements include a new fluid-level sensing technology for added assurance, easy-to-view external LED indicators that show status at a glance, quick bottle release that simplifies reagent maintenance, and integrated reliability improvements that maximize uptime.
“We are one of the first hospitals in the country to use MicroScan. It gives our staff great confidence and means we are fully geared up in advance of any outbreak,” Rachael Arkley, laboratory manager and head biomedical scientist, William Harvey Hospital, Ashford, U.K., said in a release from Beckman.